Tibotec signs licensing deal with Indian company
04 Dec 2008
Tibotec Pharmaceuticals has signed a licensing agreement with Emcure Pharmaceuticals to distribute the protease inhibitor darunavir in India.
According to Tibotec, a Johnson & Johnson (J&J) company, the contract is a royalty-free, non-exclusive agreement.
The move comes as Tibotec is working to achieve the registration of the medicine in the country, which it expects to be approved as part of a combination treatment for HIV.
Wlodek Kubiak, vice-president of worldwide access programmes at the company, said: "Tibotec believes that strong collaborations with companies such as Emcure provide the best options for HIV/Aids patients by enhancing drug access and maintaining the quality of medicines."
The chief executive of Emcure Satish Mehta also welcomed the agreement.
Earlier this week, J&J struck a definitive agreement to acquire Mentor, a supplier of medical products for the aesthetic surgery market.
Under the terms of the deal, J&J is set to purchase the firm for around $1.07 billion (£736 million) in a cash tender offer.
